Please use this identifier to cite or link to this item:
http://hdl.handle.net/2445/126584
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Sánchez Ortega, Isabel | - |
dc.contributor.author | Parody, Rocío | - |
dc.contributor.author | Servitje Bedate, Octavio | - |
dc.contributor.author | Muniesa Montserrat, Cristina | - |
dc.contributor.author | Arnan, Montserrat | - |
dc.contributor.author | Patiño, Beatriz | - |
dc.contributor.author | Sureda, Anna | - |
dc.contributor.author | Duarte, Rafael | - |
dc.date.accessioned | 2018-11-29T11:04:27Z | - |
dc.date.available | 2018-11-29T11:04:27Z | - |
dc.date.issued | 2016-06-30 | - |
dc.identifier.issn | 0353-9504 | - |
dc.identifier.uri | http://hdl.handle.net/2445/126584 | - |
dc.description.abstract | Aim To assess the toxicity, tolerance, steroid-sparing capacity, effectiveness, and response rate to imatinib and dasatinib for the treatment of severe sclerotic chronic graft-vs-host disease (scGVHD). Methods This retrospective study analyzed 8 consecutive patients with severe refractory scGVHD who received salvage therapy with imatinib. Patients intolerant and/or refractory to imatinib received dasatinib treatment. Results 7 patients discontinued imatinib treatment (1 achieved complete response, 5 were resistant and/or intolerant, and 1 developed grade IV neutropenia) and 1 patient achieved prolonged partial response, but died due to an infectious complication while on treatment 5 patients started dasatinib treatment (3 achieved partial responses and discontinued dasatinib, 1 achieved a durable partial response, but died due to a consecutive rapid pulmonary cGVHD progression and 1 with stable disease discontinued treatment due to gastroenteric intolerance). The response rate (partial and/or complete responses) for severe scGVHD was 25% for imatinib and 60% for dasatinib. Conclusion In our series, dasatinib was better tolerated, safer, steroid-sparing, and had a low incidence of infectious complications, which suggests that it may be a more effective therapeutic alternative for patients with refractory scGVHD than imatinib. Treatment of scGVHD with effective antifibrotic drugs such as TKI, which block the kinase fibrotic pathway, may be a safe and effective therapeutic option, but further studies are needed to confirm our findings. | - |
dc.format.extent | 8 p. | - |
dc.format.mimetype | application/pdf | - |
dc.language.iso | eng | - |
dc.relation.isformatof | Reproducció del document publicat a: https://doi.org/10.3325/cmj.2016.57.247 | - |
dc.relation.ispartof | Croatian Medical Journal, 2016, vol. 57, num. 3, p. 247-254 | - |
dc.relation.uri | https://doi.org/10.3325/cmj.2016.57.247 | - |
dc.rights | cc-by-nd (c) Sánchez Ortega, Isabel et al., 2016 | - |
dc.rights.uri | http://creativecommons.org/licenses/by-nd/3.0/es | - |
dc.source | Articles publicats en revistes (Ciències Clíniques) | - |
dc.subject.classification | Ús terapèutic | - |
dc.subject.classification | Efectes secundaris dels medicaments | - |
dc.subject.classification | Malalties cròniques | - |
dc.subject.other | Therapeutic use | - |
dc.subject.other | Drug side effects | - |
dc.subject.other | Chronic diseases | - |
dc.title | Imatinib and dasatinib as salvage therapy for sclerotic chronic graft-vs-host disease. | - |
dc.type | info:eu-repo/semantics/article | - |
dc.type | info:eu-repo/semantics/publishedVersion | - |
dc.identifier.idgrec | 667006 | - |
dc.date.updated | 2018-11-29T11:04:27Z | - |
dc.rights.accessRights | info:eu-repo/semantics/openAccess | - |
dc.identifier.pmid | 27374826 | - |
Appears in Collections: | Articles publicats en revistes (Ciències Clíniques) Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL)) |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
667006.pdf | 129.68 kB | Adobe PDF | View/Open |
This item is licensed under a Creative Commons License